Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 2
2003 1
2004 2
2005 1
2008 2
2009 3
2010 2
2011 1
2012 1
2018 1
2020 1
2021 4
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
[Monoclonal gammopathy of clinical importance].
Tjønnfjord GE, Schjesvold FH, Gulbrandsen N, Kvam AK. Tjønnfjord GE, et al. Among authors: gulbrandsen n. Tidsskr Nor Laegeforen. 2021 Sep 24;141(2021-13). doi: 10.4045/tidsskr.20.0981. Print 2021 Sep 28. Tidsskr Nor Laegeforen. 2021. PMID: 34596996 Free article. Norwegian.
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, Zweegman S, Zander T, Zamagni E, Wester R, Hajek R, Pantani L, Dozza L, Gay F, Cafro A, De Rosa L, Morelli A, Gregersen H, Gulbrandsen N, Cornelisse P, Troia R, Oliva S, van de Velden V, Wu K, Ypma PF, Bos G, Levin MD, Pour L, Driessen C, Broijl A, Croockewit A, Minnema MC, Waage A, Hveding C, van de Donk NWCJ, Offidani M, Palumbo GA, Spencer A, Boccadoro M, Cavo M. Sonneveld P, et al. Among authors: gulbrandsen n. J Clin Oncol. 2021 Nov 10;39(32):3613-3622. doi: 10.1200/JCO.21.01045. Epub 2021 Sep 14. J Clin Oncol. 2021. PMID: 34520219 Clinical Trial.
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.
Gregersen H, Peceliunas V, Remes K, Schjesvold F, Abildgaard N, Nahi H, Andersen NF, Vangsted AJ, Klausen TW, Helleberg C, Carlson K, Frølund UC, Axelsson P, Stromberg O, Blimark CH, Crafoord J, Tsykunova G, Eshoj HR, Waage A, Hansson M, Gulbrandsen N. Gregersen H, et al. Among authors: gulbrandsen n. Eur J Haematol. 2022 Jan;108(1):34-44. doi: 10.1111/ejh.13709. Epub 2021 Oct 11. Eur J Haematol. 2022. PMID: 34536308 Free PMC article. Clinical Trial.
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A, Brøndum RF, Johnsen HE, Mellqvist UH, Waage A, Gimsing P, Op Bruinink DH, van der Velden V, van der Holt B, Hansson M, Andersen NF, Frølund UC, Helleberg C, Schjesvold FH, Ahlberg L, Gulbrandsen N, Andreasson B, Lauri B, Haukas E, Bødker JS, Roug AS, Bøgsted M, Severinsen MT, Gregersen H, Abildgaard N, Sonneveld P, Dybkær K. Schmitz A, et al. Among authors: gulbrandsen n. BMC Cancer. 2022 Feb 5;22(1):147. doi: 10.1186/s12885-022-09184-1. BMC Cancer. 2022. PMID: 35123422 Free PMC article.
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de la Fuente FA, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA. Kaiser M, et al. Among authors: gulbrandsen n. Ann Hematol. 2021 Jan;100(1):297-302. doi: 10.1007/s00277-020-04302-0. Ann Hematol. 2021. PMID: 33106909 Free PMC article. No abstract available.
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA. Kaiser M, et al. Among authors: gulbrandsen n. Ann Hematol. 2020 Aug;99(8):1793-1804. doi: 10.1007/s00277-020-04149-5. Epub 2020 Jul 1. Ann Hematol. 2020. PMID: 32613281 Free PMC article. Clinical Trial.
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG). Hjorth M, et al. Among authors: gulbrandsen n. Eur J Haematol. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x. Epub 2012 Mar 30. Eur J Haematol. 2012. PMID: 22404182 Free PMC article. Clinical Trial.
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Björkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukås E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sørbø JH, Wisløff F, Juliusson G, Turesson I; Nordic Myeloma Study Group. Waage A, et al. Among authors: gulbrandsen n. Blood. 2010 Sep 2;116(9):1405-12. doi: 10.1182/blood-2009-08-237974. Epub 2010 May 6. Blood. 2010. PMID: 20448107 Free article. Clinical Trial.
23 results